TSX edges higher after index falls the most in seven months
GRAIL, Inc. NASDAQ:GRAL President, Joshua J. Ofman, sold 14,979 shares of common stock on October 15 and 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed in two separate transactions at prices ranging from $76.0276 to $82.01, resulting in total proceeds of approximately $1.17 million. The stock, which has surged over 500% in the past year and currently trades at $86.27, appears overvalued according to InvestingPro analysis.
On October 15, Ofman sold 8,865 shares at $76.0276 per share. The following day, October 16, he sold an additional 6,114 shares at $82.01 per share. Following these transactions, Ofman directly owns 381,818 shares of GRAIL, Inc., which currently has a market capitalization of $2.7 billion and averages 930,000 shares traded daily.InvestingPro subscribers have access to 13 additional key insights about GRAIL, including detailed valuation metrics and financial health indicators. Access the comprehensive Pro Research Report for deep-dive analysis.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. The stock is currently trading near its 52-week high of $89.57, with technical indicators suggesting overbought conditions.
In other recent news, Grail Inc has reported a significant earnings beat for the second quarter of 2025. The company posted an earnings per share of -$3.18, exceeding the expected -$4.12, and marking an earnings surprise of 22.82%. Revenue for the quarter increased by 11% year-over-year, reaching $35.5 million. Additionally, Grail has entered into a strategic collaboration with Samsung, involving a $110 million investment to bring its Galleri multi-cancer early detection test to key Asian markets. As part of this partnership, Samsung C&T will distribute the test exclusively in South Korea, with potential expansion to Japan and Singapore. In another development, Grail plans to present the initial results of its PATHFINDER 2 study at the European Society for Medical Oncology Congress in Berlin next month. This study is the largest of its kind in the U.S. for multi-cancer early detection in a population without clinical suspicion of cancer. The results will be submitted to the FDA as part of the Galleri Premarket Approval Application.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.